EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells

Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma

“…Attempts to facilitate stem cell mobilization have included the use of EPO in combination with G-CSF after mobilization chemotherapy with ifosfamide, epirubicin, and etoposide; 36 pegfilgrastim; 14 dexamethasone, CY, etoposide, and cisplatin; 37 or CY, doxorubicin, and dexamethasone. 38 Cytokine-only mobilization regimens were well tolerated, but the utility is limited by lower stem cell yield.…”

Small molecule Me6TREN mobilizes hematopoietic stem/progenitor cells by activating MMP-9 expression and disrupting SDF-1/CXCR4 axis

“…Moreover, some patients or normal donors respond poorly to G-CSF. 16 Among other agents capable of mobilizing HSPCs, plerixafor (AMD3100) is the only molecule used for patients with non-Hodgkin lymphoma and multiple myeloma that has been approved by the US Food and Drug Administration (FDA). 17,18 Clinical studies have shown that plerixafor may be a more rapid and less toxic alternative to traditional G-CSF-based mobilization.…”

Sources of Hematopoietic Stem Cells

“…However, EPO use is generally regarded as inefficient and, as such, has not become a standard of care. Studies evaluating the mobilization efficacy of EPO plus G-CSF or G-CSF alone in various doses have generated mixed results [120][121][122]. Further investigation is required to ascertain the clinical benefits of EPO combined with G-CSF [123].…”